{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:04:01Z","timestamp":1787965441412,"version":"build-2784847793"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Peloton Advantage, LLC"},{"name":"AstraZeneca Rare Disease"},{"DOI":"10.13039\/100006396","name":"Alexion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypophosphatasia (HPP) is a rare, inherited metabolic disease caused by deficient activity of tissue-nonspecific alkaline phosphatase (TNSALP). Efzimfotase alfa (ALXN1850) is a second-generation TNSALP enzyme replacement therapy in development for HPP. This first-in-human open-label, dose-escalating phase 1 trial evaluated efzimfotase alfa safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. Fifteen adults (5\/cohort) with HPP received efzimfotase alfa in doses of 15\u00a0mg (cohort 1), 45\u00a0mg (cohort 2), or 90\u00a0mg (cohort 3) as one intravenous (i.v.) dose followed by 3 weekly subcutaneous (s.c.) doses. The primary objective was to assess safety and tolerability. Secondary objectives included pharmacokinetics, pharmacodynamics of ALP substrates known to be biomarkers of disease (inorganic pyrophosphate [PPi] and pyridoxal 5\u2032-phosphate [PLP]) and immunogenicity. Treatment-emergent adverse events (TEAEs) occurred in 12 (80%) participants. Eight (53%) participants had injection site reactions (ISRs), observed after 10 of 41 (24%) s.c. injections. Most ISR TEAEs were mild and resolved within 1\u20132\u00a0d. Peak and total exposures of efzimfotase alfa increased in a greater-than-dose proportional manner over the range of 15\u201390\u00a0mg after i.v. and s.c. dosing. The arithmetic mean elimination half-life was approximately 6\u00a0d; absolute bioavailability was 28.6%\u201336.8% over the s.c. dose range of 15\u201390\u00a0mg. Dose-dependent reductions in plasma concentrations of PPi and PLP relative to baseline reached nadir in the first week after i.v. dosing and were sustained for 3\u20134\u00a0wk after the last s.c. dose. Four (27%) participants tested positive for antidrug antibodies (ADAs), 3 of whom were ADA positive before the first dose of efzimfotase alfa. ADAs had no apparent effect on efzimfotase alfa pharmacokinetics\/pharmacodynamics. No participants had neutralizing antibodies. Efzimfotase alfa demonstrated acceptable safety, tolerability, and pharmacokinetic profiles and was associated with sustained reductions in biomarkers of disease in adults with HPP, supporting further evaluation in adult and pediatric patients.<\/jats:p>\n               <jats:p>Registration: ClinicalTrials.gov NCT04980248 (https:\/\/clinicaltrials.gov\/study\/NCT04980248).<\/jats:p>","DOI":"10.1093\/jbmr\/zjae128","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T10:59:39Z","timestamp":1723546779000},"page":"1412-1423","source":"Crossref","is-referenced-by-count":16,"title":["Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-9138","authenticated-orcid":false,"given":"Kathryn M","family":"Dahir","sequence":"first","affiliation":[{"name":"Program for Metabolic Bone Disorders, Vanderbilt University Medical Center , Nashville, TN 37232-8148,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Shannon","sequence":"additional","affiliation":[{"name":"Development , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]},{"name":"Alexion, AstraZeneca Rare Disease , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Dunn","sequence":"additional","affiliation":[{"name":"Development , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]},{"name":"Alexion, AstraZeneca Rare Disease , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Voegtli","sequence":"additional","affiliation":[{"name":"Development , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]},{"name":"Alexion, AstraZeneca Rare Disease , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunming","family":"Dong","sequence":"additional","affiliation":[{"name":"Development , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]},{"name":"Alexion, AstraZeneca Rare Disease , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Hasan","sequence":"additional","affiliation":[{"name":"Development , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]},{"name":"Alexion, AstraZeneca Rare Disease , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Development , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]},{"name":"Alexion, AstraZeneca Rare Disease , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Pelto","sequence":"additional","affiliation":[{"name":"Bioanalytical and Biomarker Development, Alexion, AstraZeneca Rare Disease , New Haven, CT 06510,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jian","family":"Pan","sequence":"additional","affiliation":[{"name":"Development , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]},{"name":"Alexion, AstraZeneca Rare Disease , Regulatory and Safety, , Boston, MA 02210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"20","key":"2024092612112981400_ref1","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1073\/pnas.85.20.7666","article-title":"A missense mutation in the human liver\/bone\/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia","volume":"85","author":"Weiss","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024092612112981400_ref2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1749-6632.2010.05387.x","article-title":"Physiological role of alkaline phosphatase explored in hypophosphatasia","volume":"1192","author":"Whyte","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"suppl 2","key":"2024092612112981400_ref3","first-page":"380","article-title":"Hypophosphatasia","volume":"10","author":"Rockman-Greenberg","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"issue":"12","key":"2024092612112981400_ref4","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s00198-021-06025-y","article-title":"Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024092612112981400_ref5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bone.2013.01.024","article-title":"Clinical spectrum of hypophosphatasia diagnosed in adults","volume":"54","author":"Berkseth","year":"2013","journal-title":"Bone"},{"issue":"1","key":"2024092612112981400_ref6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","article-title":"Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry","volume":"20","author":"H\u00f6gler","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"2024092612112981400_ref7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13023-022-02393-8","article-title":"Clinical profiles of treated and untreated adults with hypophosphatasia in the global HPP registry","volume":"17","author":"Dahir","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2024092612112981400_ref8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00198-023-06859-8","article-title":"The challenge of hypophosphatasia diagnosis in adults: results from the HPP international working group literature surveillance","volume":"35","author":"Brandi","year":"2024","journal-title":"Osteoporosis Int"},{"issue":"1","key":"2024092612112981400_ref9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-2-40","article-title":"Hypophosphatasia","volume":"2","author":"Mornet","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"2024092612112981400_ref10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/B978-0-12-804182-6.00028-9","volume-title":"Genetics of Bone Biology and Skeletal Disease","author":"Whyte","year":"2018","edition":"2nd ed."},{"key":"2024092612112981400_ref11","volume-title":"Strensiq [Package Insert]","year":"2020"},{"key":"2024092612112981400_ref12","volume-title":"Strensiq [Summary of Product Characteristics]","year":"2020"},{"key":"2024092612112981400_ref13","volume-title":"Strensiq (Asfotase Alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP)","author":"Alexion Pharmaceuticals","year":"2015."},{"key":"2024092612112981400_ref14","doi-asserted-by":"crossref","first-page":"115664","DOI":"10.1016\/j.bone.2020.115664","article-title":"Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia","volume":"142","author":"Seefried","year":"2021","journal-title":"Bone"},{"key":"2024092612112981400_ref15","year":"2021"},{"issue":"10","key":"2024092612112981400_ref16","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/jcph.1870","article-title":"Pharmacokinetics of asfotase alfa in adult patients with pediatric-onset hypophosphatasia","volume":"61","author":"Pan","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2024092612112981400_ref17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"key":"2024092612112981400_ref18","volume-title":"Application Number: 125513orig1s000. Clinical Pharmacology and Biopharmaceutics Review(s)","author":"Asfotase Alfa (Strensiq)","year":"2015"},{"issue":"10","key":"2024092612112981400_ref19","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia [with supplementary appendix]","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med"},{"issue":"1-2","key":"2024092612112981400_ref20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ymgme.2018.07.006","article-title":"Pyridoxal 5\u2032-phosphate and related metabolites in hypophosphatasia: effects of enzyme replacement therapy","volume":"125","author":"Akiyama","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"7","key":"2024092612112981400_ref21","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1210\/jc.2018-02335","article-title":"Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study","volume":"104","author":"Hofmann","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024092612112981400_ref22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial [with supplementary appendix]","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2024092612112981400_ref23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024092612112981400_ref24","doi-asserted-by":"crossref","first-page":"e10395","DOI":"10.1002\/jbm4.10395","article-title":"Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia","volume":"4","author":"Genest","year":"2020","journal-title":"JBMR Plus"},{"issue":"1","key":"2024092612112981400_ref25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-024-03048-6","article-title":"Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry","volume":"19","author":"Kishnani","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2024092612112981400_ref26","doi-asserted-by":"crossref","first-page":"e85971","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia [with on-line only supplement]","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae128\/59006874\/zjae128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/10\/1412\/59350963\/zjae128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/10\/1412\/59350963\/zjae128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T12:11:53Z","timestamp":1727352713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/10\/1412\/7732140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,9,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae128","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,13]]}}}